Strathmore Capital Advisors’s AbbVie ABBV Stock Holding History

Strathmore Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Buy	3,965 +19	+0.5%	+$4.09K	0.27%	44
2026 Q1	$784K	Buy	3,946 +143	+4%	+$31.7K	0.22%	67
2025 Q4	$869K	Sell	3,803 -115	-3%	-$26.2K	0.28%	45
2025 Q3	$907K	Sell	3,918 -132	-3%	-$26.9K	0.37%	39
2025 Q2	$772K	Buy	+4,050	New	+$753K	0.34%	42

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Strathmore Capital Advisors's ABBV Position: Q2 2026 in Review

Strathmore Capital Advisors increased its AbbVie (ABBV) stake by 0.48% in Q2 2026, buying an estimated $4.09K and bringing the position to 3,965 shares worth $1.02M. The position accounts for 0.27% of the portfolio, ranked #44.

Strathmore Capital Advisors first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Strathmore Capital Advisors held 3,965 shares of AbbVie worth $1.02M as of Q2 2026.
Strathmore Capital Advisors bought 19 AbbVie shares in Q2 2026, an estimated $4.09K.
AbbVie made up 0.27% of Strathmore Capital Advisors's portfolio in Q2 2026, its #44 holding.
Strathmore Capital Advisors first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Strathmore Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.